查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1378889

急性骨髓性白血病治疗市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球急性骨髓性白血病治疗市场规模达到10.732亿美元。展望未来， IMARC Group预计到2028年市场规模将达到21.991亿美元，2022-2028年复合年增长率（CAGR）为12.7%。

急性骨髓性白血病（AML）是指导致异常细胞快速生长的克隆性恶性肿瘤。它主要影响骨髓和白血球 (WBC)，其特征是皮肤变色、呼吸困难、疲劳、体温高、体重减轻、牙龈出血和流鼻血。一些常用的 AML 疗法包括化疗、免疫、标靶和荷尔蒙疗法以及外科手术。这些疗法通常与干细胞移植相结合，以提高疗效、减少併发症并增强身体的免疫系统。

全球白血病盛行率不断上升是推动市场成长的关键因素之一。此外，老年人口的增加也推动了市场的成长，老年人口更容易罹患此类疾病。 AML 主要是由影响血球生成水平的体内基因突变引起的。与此一致的是，联合疗法和标靶疗法的广泛采用以及对癌症治疗可用替代方案的认识不断提高也有利于市场成长。此外，改良的免疫毒素、烷化剂、单株抗体和多重抗药性调节剂的出现是另一个主要的生长诱导因素。这些疗法提供了长期的结果、更高的功效、对白血病细胞的早期和准确识别，并减少了癌症復发的机会。其他因素，包括肿瘤学领域的广泛研究和开发（R&D）活动，以及现有医疗基础设施的显着改善，预计将进一步推动市场发展。

本报告回答的关键问题：

  • 迄今为止，全球急性骨髓性白血病治疗市场表现如何，未来几年将如何表现？
  • COVID-19 对全球急性骨髓性白血病治疗市场有何影响？
  • 主要区域市场有哪些？
  • 根据治疗类型的市场划分是怎样的？
  • 根据药物类型分類的市场是怎么样的？
  • 根据给药途径，市场的分化为何？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球急性髓性白血病治疗市场的结构如何？谁是主要参与者？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球急性骨髓性白血病治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按治疗类型分類的市场区隔

  • 阿糖胞苷
    • 市场走向
    • 市场预测
  • 蒽环类药物
    • 市场走向
    • 市场预测
  • 烷基化剂
    • 市场走向
    • 市场预测
  • 抗代谢药
    • 市场走向
    • 市场预测
  • 酪胺酸激酶抑制剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：按药物类型分類的市场细分

  • 小分子药物
    • 市场走向
    • 市场预测
  • 生物製药
    • 市场走向
    • 市场预测

第 8 章：按管理途径分類的市场

  • 口服
    • 市场走向
    • 市场预测
  • 注射剂
    • 市场走向
    • 市场预测

第 9 章：按地区分類的市场区隔

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Celgene
    • Roche Holding AG
    • Gilead Sciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112023A3129

Abstract

The global acute myeloid leukemia therapeutics market size reached US$ 1,073.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,199.1 Million by 2028, exhibiting a growth rate (CAGR) of 12.7% during 2022-2028.

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acute myeloid leukemia therapeutics market report, along with forecasts at the global, regional and country levels from 2023-2028. Our report has categorized the market based on treatment type, drug type and route of administration.

Breakup by Treatment Type:

Cytarabine

Anthracycline Drugs

Alkylating Agents

Anti-Metabolites

Tyrosine Kinase Inhibitors

Others

Breakup by Drug Type:

Small Molecule Drugs

Biopharmaceuticals

Breakup by Route of Administration:

Oral

Injectables

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Cytarabine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anthracycline Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alkylating Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Anti-Metabolites
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tyrosine Kinase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biopharmaceuticals
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Celgene
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Roche Holding AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Gilead Sciences Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Acute Myeloid Leukemia Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Treatment Type (in %), 2022
  • Figure 5: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Route of Administration (in %), 2022
  • Figure 7: Global: Acute Myeloid Leukemia Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Acute Myeloid Leukemia Therapeutics (Cytarabine) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Acute Myeloid Leukemia Therapeutics (Anthracycline Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Acute Myeloid Leukemia Therapeutics (Alkylating Agents) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Acute Myeloid Leukemia Therapeutics (Anti-Metabolites) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Acute Myeloid Leukemia Therapeutics (Tyrosine Kinase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Acute Myeloid Leukemia Therapeutics (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Acute Myeloid Leukemia Therapeutics (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Acute Myeloid Leukemia Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Acute Myeloid Leukemia Therapeutics (Biopharmaceuticals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Acute Myeloid Leukemia Therapeutics (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Acute Myeloid Leukemia Therapeutics (Injectables) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Middle East and Africa: Acute Myeloid Leukemia Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 77: Global: Acute Myeloid Leukemia Therapeutics Industry: SWOT Analysis
  • Figure 78: Global: Acute Myeloid Leukemia Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Acute Myeloid Leukemia Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acute Myeloid Leukemia Therapeutics Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 3: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Acute Myeloid Leukemia Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Acute Myeloid Leukemia Therapeutics Market: Competitive Structure
  • Table 7: Global: Acute Myeloid Leukemia Therapeutics Market: Key Players